Philippe Maitre To Head Onxeo US
This article was originally published in Scrip
Oncology focused Onxeo SA. has appointed Philippe Maitre head of its new US subsidiary as executive vice president and chief of US operations. Maitre brings over 35 years' experience to the company and previously served as CEO and co-founder of the biotech mAbRx. Prior to this, he was CEO at the cancer vaccine company Anosys. Onxeo's new US subsidiary is headquartered in New York.